ralf_huss

German biotech Apceth appoints Prof. Ralf Huss

pharmafile | October 19, 2011 | Appointment | Research and Development appointment, research and development 

Munich-based biotech Apceth has appointed Prof Ralf Huss to its management board.

Prof Huss moves to the company from Roche, where he served as global head of the pharma firm’s therapeutic cell initiative.

He already has a long-standing relationship with Apceth, which specialises in the translational development and manufacturing of innovative cell therapy products, and in his new role will focus on the pre-clinical and early development of cell-based therapeutics and external innovation.

Advertisement

Apceth majority shareholder Dr Thomas Strüngmann explained: “Ralf Huss has been a founding member of Apceth. We are delighted that he has now decided to join the operational team in Apceth.”

 Prof Huss worked at Roche Diagnostics GmbH in Pharmaceutical Research & Early Development (pRED) in Penzberg, Germany from 2005.

In addition to his other positions, he remains adjunct professor for regenerative medicine at Wake Forest Institute for Regenerative Medicine in Winston-Salem in the US.

Apceth was set up in 2007 as a start-up company with funding from  the founders and former owners of pharmaceutical manufacturer Hexal, including Dr Strüngmann, which Novartis acquired in 2005.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content